ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

RTSN vs TNXP // RSI-14 & 200D SMA MOMENTUM

Retension Pharmaceuticals Inc. (NASDAQ) VS. Tonix Pharmaceuticals Holding Corp. (NASDAQ) • 15-METRIC TALLY: RTSN 2 — TNXP 0
▲ RSI-14 & 200D SMA MOMENTUM LEADER: RTSN
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RTSN VS. TNXP) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC RTSN TNXP SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 49.30% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) — -35.00% — TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 29.80% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality — 5/9 — TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 54.4 17.4 +36.99 RTSN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $93.2M $90.6M $2.7M RTSN /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR RTSN REV TNXP REV RTSN GROSS % TNXP GROSS % RTSN FCF TNXP FCF
FY 2025 — $13.1M — 49.3% — -$103.2M
FY 2024 — $10.1M — 23.1% — -$61.0M
FY 2023 — $7.8M — — — -$102.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RTSN // BETA —
TNXP // BETA —